Table 3.
COMMUNICATION (Written) | OUTREACH | ||
---|---|---|---|
Supplementary information about clinical trials OR (95% CI) | Any materials to facilitate recruitment into clinical trials OR (95% CI) | Outreach efforts OR (95% CI) | |
Type of practicea | |||
Solo or group practice | ref | ref | ref |
Public community health center/hospital | 1.02 (0.54-1.92) | 0.28 (0.13-0.64)2 | 1.80 (0.91-3.29) |
VA, private or community hospital | 0.60 (0.22-1.60) | 0.29 (0.09-0.94)3 | 1.19 (0.44-3.22) |
University/teaching hosp/research or cancer institute | 0.66 (0.31-1.40) | 0.40 (0.15-1.07) | 2.20 (1.03-4.70)3 |
Number of phase III clinical trialsb | |||
≤2 phase III trials | ref | ref | ref |
≥3 phase III trials | 1.55 (0.90-2.66) | 1.43 (0.73-2.83) | 1.07 (0.62-1.85) |
Percent of Latinas in patient populationb | |||
<10% | ref | ref | ref |
≥10% | 1.64 (0.91-2.96) | 0.99 (0.47-2.07) | 1.97 (1.07-3.60)3 |
Percent of African Americans in patient populationb | |||
<10% | ref | ref | ref |
≥10% | 1.10 (0.62-1.96) | 1.33 (0.63-2.81) | 1.04 (0.58-1.86) |
Percent of patients who are LEPb | |||
<10% | ref | ref | ref |
≥10% | 1.37 (0.72-2.62) | 0.46 (0.21-0.99)3 | 1.42 (0.74-2.73) |
Analyses adjusted for state
Analyses adjusted for state and practice type
1 p<0.05;
p<0.01
p<0.05